Telix Pharmaceuticals and the Oncidium foundation announced positive initial results from the NOBLE Registry, a real-world evidence study of TLX599-CDx for prostate cancer imaging. The study, published in the •European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports•, demonstrated a management change in 42.5% of the 40 patients across six countries who received TLX599-CDx and underwent SPECT imaging. The study aims to improve access to advanced prostate cancer imaging, particularly in areas with limited access to PET/CT scanners.

These findings are particularly important for patients in regions with limited resources or geographical barriers to advanced imaging technology. The positive results reinforce the potential of TLX599-CDx as a viable and more accessible alternative to traditional PET-based PSMA imaging, potentially improving early diagnosis and disease management for prostate cancer patients globally. The wider availability of SPECT scanners and the established supply chain for 99mTc, used in TLX599-CDx, makes this approach potentially more cost-effective and practical for broader implementation.

The NOBLE Registry enrolled 40 patients across six countries. The initial data demonstrated a 42.5% change in patient management after receiving the TLX599-CDx and undergoing planar and SPECT imaging. Importantly, no adverse events related to the imaging agent were reported in the study. This successful initial phase highlights the potential for a broader rollout of the imaging agent, pending further clinical investigation. The use of readily available SPECT technology combined with the established 99mTc supply chain offers a promising pathway towards more equitable access to advanced prostate cancer diagnostics.

The promising initial results pave the way for further clinical activity within the NOBLE Registry. This includes potential collaborations to expand access to TLX599-CDx and the exploration of technetium-99m and rhenium-188 as a theranostic pair in prostate cancer. This points towards a future where advanced diagnostic imaging for prostate cancer is more accessible globally, improving patient outcomes and potentially transforming the diagnostic landscape for this prevalent disease.

Source link: https://www.globenewswire.com/news-release/2024/12/30/3002869/0/en/NOBLE-Registry-Update-TLX599-CDx-PSMA-SPECT-Imaging-of-Prostate-Cancer-Published-in-EJNMMI-Reports.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.